Patents by Inventor Tarak D. Mody
Tarak D. Mody has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030232800Abstract: The present invention provides certain non-symmetric tripyrranes; that is, tripyrranes that do not contain a mirror plane of symmetry perpendicular to the plane containing the tripyrrane. Further, the invention includes texaphyrin compounds and sapphyrin compounds, as well as other polypyrrolic macrocycles, prepared using tripyrranes of Formula I as a precursor. These macrocycles are characterized by a tripyrrolic portion of the macrocyclic ring having substituents that cause the heterocycle to lack a plane of symmetry perpendicular to the plane of the macrocycle.Type: ApplicationFiled: February 26, 2003Publication date: December 18, 2003Inventors: Tarak D Mody, Joshua Galanter
-
Patent number: 6638924Abstract: Novel derivatives of metallotexaphyrins are prepared by modifying the apical ligands associated with the central metal component of a metallotexaphyrin.Type: GrantFiled: August 28, 2001Date of Patent: October 28, 2003Assignee: Pharmacyclics, Inc.Inventors: Tarak D. Mody, Joshua Galanter
-
Publication number: 20030073679Abstract: Novel derivatives of metallotexaphyrins are prepared by modifying the apical ligands associated with the central metal component of a metallotexaphyrin.Type: ApplicationFiled: August 28, 2001Publication date: April 17, 2003Inventors: Tarak D. Mody, Joshua Galanter
-
Patent number: 6375930Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen.Type: GrantFiled: November 20, 1997Date of Patent: April 23, 2002Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Stuart W. Young, Meredith Wright, Jonathan L. Sessler, Tarak D. Mody, Darren Magda
-
Publication number: 20020006378Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen.Type: ApplicationFiled: November 20, 1997Publication date: January 17, 2002Inventors: STUART W. YOUNG, MEREDITH WRIGHT, JONATHAN L. SESSLER, TARAK D. MODY, DARREN MAGDA
-
Patent number: 6072038Abstract: The invention relates to the field of radiation sensitizers and the use of texaphyrins for radiation sensitization and other conditions for which X-ray radiation has proven to be therapeutic.Type: GrantFiled: June 25, 1998Date of Patent: June 6, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi
-
Patent number: 6069140Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: November 14, 1997Date of Patent: May 30, 2000Assignee: The Board of Regents University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi
-
Patent number: 5994535Abstract: The present invention is directed to methods for synthesizing water soluble hydroxy-substituted texaphyrins retaining lipophilicity. The synthesis comprises condensing a diformyltripyrrole with an ortho-phenylenediamine to give a nonaromatic texaphyrin having at least one hydroxy substituent, and oxidizing the condensation product to form an aromatic texaphyrin metal complex having at least one hydroxy substituent. These expanded porphyrin-like macrocycles may be used for magnetic resonance imaging and for photodynamic therapy in the treatment of atheroma and tumors.Type: GrantFiled: February 26, 1998Date of Patent: November 30, 1999Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5969111Abstract: Texaphyrins substituted with imidazda are provided.Type: GrantFiled: February 4, 1997Date of Patent: October 19, 1999Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody, Darren Magda, Vladimir A. Kral
-
Patent number: 5888997Abstract: The invention relates to the field of radiation sensitizers and the use of texaphyrins for radiation sensitization and other conditions for which X-ray radiation has proven to be therapeutic.Type: GrantFiled: February 4, 1997Date of Patent: March 30, 1999Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Anthony Harriman, Richard A. Miller, Darren Magda, Tarak D. Mody, Gregory W. Hemmi
-
Patent number: 5801229Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: September 13, 1996Date of Patent: September 1, 1998Assignee: The Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral
-
Patent number: 5756726Abstract: Novel texaphyrin compounds having improved functionalization are described. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus are potentially useful for treatments performed with singlet oxygen. Several of the metallotexaphyrin complexes absorb light in the physiologically important range of 690-880 nm. The complexes form long-lived triplet states and thus may act as efficient photosensitizers for generation of singlet oxygen.Type: GrantFiled: June 6, 1995Date of Patent: May 26, 1998Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5733903Abstract: The present invention relates to the use of water-soluble texaphyrin-diamagnetic metal complexes retaining lipophilicity as photosensitizers in the treatment of benign and malignant neoplastic tissue.Type: GrantFiled: July 10, 1996Date of Patent: March 31, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5632970Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocatization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 7, 1995Date of Patent: May 27, 1997Assignees: Board of Regents, The University of Texas, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5601802Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. These texaphyrin metal complexes having enhanced stability are useful for localization, magnetic resonance imaging, radiosensitization, radiation therapy, fluorescence imaging, photodynamic therapy, RNA hydrolysis, DNA photocleavage, and applications requiring singlet oxygen production for cytotoxicity. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical.Type: GrantFiled: June 7, 1995Date of Patent: February 11, 1997Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5599923Abstract: Texaphyrin metal complexes having improved functionalization including the addition of electron donating groups to positions 12, 15, 18 and/or 21 and/or the addition of electron withdrawing groups to positions 15 or 18 of the macrocycle. Electron donating groups at positions 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis, these texaphyrin metal complexes having enhanced stability are useful for localization, magnetic resonance imaging, radiosensitization, radiation therapy, fluorescence imaging, photodynamic tumor therapy and applications requiring singlet oxygen production for cytotoxicity. Electron withdrawing groups at positions 15 or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential are useful for radiosensitization applications.Type: GrantFiled: February 15, 1994Date of Patent: February 4, 1997Assignees: Board of Regents, University of TX, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi
-
Patent number: 5599928Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.Type: GrantFiled: June 2, 1995Date of Patent: February 4, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5591422Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. These texaphyrin metal complexes having enhanced stability are useful for localization, radiosensitization and radiation therapy. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential are useful for radiation sensitization applications.Type: GrantFiled: June 6, 1995Date of Patent: January 7, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5587371Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 24, 1996Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5583220Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: May 24, 1995Date of Patent: December 10, 1996Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Jonathan L. Sessler, Anthony M. Harriman, Richard A. Miller, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral, Darren Magda